CN102014895A - 组合抗癌剂 - Google Patents

组合抗癌剂 Download PDF

Info

Publication number
CN102014895A
CN102014895A CN2009801154644A CN200980115464A CN102014895A CN 102014895 A CN102014895 A CN 102014895A CN 2009801154644 A CN2009801154644 A CN 2009801154644A CN 200980115464 A CN200980115464 A CN 200980115464A CN 102014895 A CN102014895 A CN 102014895A
Authority
CN
China
Prior art keywords
lucanthone
antimetabolite
treatment
administration
effective dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2009801154644A
Other languages
English (en)
Chinese (zh)
Inventor
古鲁·雷迪
路吉·莱纳兹
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Spectrum Pharmaceuticals Inc
Original Assignee
Spectrum Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Spectrum Pharmaceuticals Inc filed Critical Spectrum Pharmaceuticals Inc
Publication of CN102014895A publication Critical patent/CN102014895A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/382—Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CN2009801154644A 2008-02-29 2009-02-20 组合抗癌剂 Pending CN102014895A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3283108P 2008-02-29 2008-02-29
US61/032,831 2008-02-29
PCT/US2009/034629 WO2009108573A1 (en) 2008-02-29 2009-02-20 Combination anti-cancer agents

Publications (1)

Publication Number Publication Date
CN102014895A true CN102014895A (zh) 2011-04-13

Family

ID=40566524

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2009801154644A Pending CN102014895A (zh) 2008-02-29 2009-02-20 组合抗癌剂

Country Status (13)

Country Link
US (1) US20090221615A1 (enExample)
EP (1) EP2257285A1 (enExample)
JP (1) JP5590560B2 (enExample)
KR (1) KR20100126453A (enExample)
CN (1) CN102014895A (enExample)
AU (1) AU2009219464B2 (enExample)
BR (1) BRPI0908398A2 (enExample)
CA (1) CA2717100A1 (enExample)
IL (1) IL207859A (enExample)
MX (1) MX2010009502A (enExample)
RU (1) RU2516027C2 (enExample)
WO (1) WO2009108573A1 (enExample)
ZA (1) ZA201006123B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6182313B2 (ja) * 2010-03-08 2017-08-16 スペクトラム ファーマシューティカルズ インコーポレイテッド 癌治療のためのチオキサントンをベースとしたオートファジー阻害剤療法
EP2425830A1 (en) 2010-09-03 2012-03-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Synergistic drug combination for the treatment of cancer
WO2023114245A2 (en) * 2021-12-14 2023-06-22 Radin Daniel Pierce Compositions and methods for treating cancers of the central nervous system (cns), including glioblastoma and chemoresistant cns tumors, and related compositions and methods for inhibiting and eliminating cns cancer stem cells

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ504108A (en) * 1997-09-26 2002-06-28 Noven Pharma Bioadhesive compositions comprising a polyvinylpyrrolidone polymer and methods for topical administration of active agents
US6391911B1 (en) * 1999-02-26 2002-05-21 Robert E. Bases Coadministration of lucanthone and radiation for treatment of cancer
EP1971338B8 (en) * 2005-12-22 2011-09-21 AstraZeneca AB Combination of zd6474 and pemetrexed
JP2009520787A (ja) * 2005-12-22 2009-05-28 アストラゼネカ アクチボラグ Ａｚｄ２１７１およびペメトレキセドの組み合わせ

Also Published As

Publication number Publication date
KR20100126453A (ko) 2010-12-01
WO2009108573A1 (en) 2009-09-03
BRPI0908398A2 (pt) 2015-08-11
IL207859A (en) 2015-09-24
RU2010139840A (ru) 2012-04-10
RU2516027C2 (ru) 2014-05-20
MX2010009502A (es) 2010-11-10
ZA201006123B (en) 2011-05-25
IL207859A0 (en) 2010-12-30
CA2717100A1 (en) 2009-09-03
AU2009219464A1 (en) 2009-09-03
EP2257285A1 (en) 2010-12-08
JP5590560B2 (ja) 2014-09-17
US20090221615A1 (en) 2009-09-03
AU2009219464B2 (en) 2015-04-09
JP2011513315A (ja) 2011-04-28

Similar Documents

Publication Publication Date Title
US20070281040A1 (en) Combination therapy of hedgehog inhibitors, radiation and chemotherapeutic agents
US6391911B1 (en) Coadministration of lucanthone and radiation for treatment of cancer
JP5642892B2 (ja) 多形膠芽腫の治療のためのマシテンタンを含有する組み合わせ剤
AU2009219464B2 (en) Combination anti-cancer agents
US20230038138A1 (en) Combination therapy for treating cancer
CN113747898A (zh) 用于联合治疗软组织肉瘤的喹啉衍生物
CN111939165B (zh) 非天然人参皂苷3β-O-Glc-DM在制备预防或治疗胶质母细胞瘤药物中的应用
CN101155600B (zh) 放射线治疗增强剂
CN117083086A (zh) 腺苷二磷酸核糖在放射和／或抗癌治疗辅助疗法中的应用
CN115190800A (zh) 一种brd4抑制剂的用途
WO2021097401A1 (en) Combination therapy with protein kinase b activation inhibitor to treat cancer
CN111821302A (zh) 用于联合治疗软骨肉瘤的喹啉类化合物
US12357650B2 (en) Methods and compositions for cancer therapies that include delivery of halogenated thymidines and thymidine phosphorlylase inhibitors in combination with radiation
CN120361228B (zh) 一种葡萄糖激酶激活剂与pi3k抑制剂的组合物
EP4093398B1 (en) Abt-751 and ionizing radiation for use in treating a brain tumor
CN107137406B (zh) 一种Hedgehog信号通路抑制剂在制备治疗EGFR过度表达的癌症的药物中的用途
WO2025237957A1 (en) Composition for treatment of estrogen-dependent cancer comprising a mettl-3 inhibitor and a topoisomerase-1 inhibitor
HK40065487A (en) Quinoline derivative used for soft tissue sarcoma combination therapy

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Open date: 20110413